Management of Liver Cirrhosis During Spironolactone Shortage

Introduction to Alternative Therapies

Amiloride is recommended as an alternative to spironolactone for patients with liver cirrhosis during a medication shortage, with a dose of 10-40 mg/day, according to the American Association for the Study of Liver Diseases 1, 2
The European Association for the Study of the Liver suggests that amiloride can be directly substituted for spironolactone at a dose of 10-40 mg/day, which is approximately 1/10 of the spironolactone dose 3, 4

Amiloride acts on the distal tubule like spironolactone and maintains the critical aldosterone-antagonist mechanism needed in cirrhotic patients, with high strength of evidence 4
The American College of Gastroenterology recommends amiloride as the appropriate substitute for spironolactone in cirrhotic patients, with a typical starting dose of 10 mg daily, which can be titrated up to 40 mg daily based on response 2

The American Heart Association recommends monitoring serum electrolytes, particularly potassium, as with any potassium-sparing diuretic, with moderate strength of evidence 4
The European Society of Gastroenterology suggests assessing weight loss daily, without peripheral edema, weight loss should not exceed 0.5 kg/day, with low strength of evidence 3
The International Ascites Club recommends monitoring spot urine Na/K ratio, a ratio >1 represents adequate sodium excretion, with high strength of evidence 4

The American Association for the Study of Liver Diseases states that eplerenone has not been extensively studied in cirrhosis and ascites, but may be considered as an alternative, with low strength of evidence 1, 5
The European Association for the Study of the Liver suggests that furosemide alone is less effective than aldosterone antagonists in cirrhosis, but may be used with careful potassium monitoring, with moderate strength of evidence 6, 7

The American College of Gastroenterology recommends avoiding hydrochlorothiazide as it can cause rapid development of hyponatremia when used in cirrhotic patients, with high strength of evidence 1, 8
The American Heart Association suggests that loop diuretics alone are less effective and physiologically inappropriate as first-line therapy in cirrhosis, with moderate strength of evidence 6, 3
The European Society of Gastroenterology recommends avoiding angiotensin-converting enzyme inhibitors as they can aggravate hypotension in cirrhotic patients, with low strength of evidence 6, 9

The International Ascites Club suggests considering therapeutic paracentesis as a temporary measure for patients with tense ascites who cannot access any appropriate diuretics, with moderate strength of evidence 8, 5
The American Association for the Study of Liver Diseases recommends administering albumin (8g/L of ascites removed) after large volume paracentesis (>5L), with high strength of evidence 10